DaShenLin Pharmaceutical Group Co., Ltd. (SHA: 603233)
China
· Delayed Price · Currency is CNY 15.58
-0.03 (-0.19%)
Nov 29, 2024, 3:00 PM CST
DaShenLin Pharmaceutical Group Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 25,939 | 23,931 | 20,780 | 16,759 | 14,262 | 10,882 | Upgrade
|
| Other Revenue | 599.94 | 599.94 | 467.67 | - | 320.64 | 259.06 | Upgrade
|
| Revenue | 26,539 | 24,531 | 21,248 | 16,759 | 14,583 | 11,141 | Upgrade
|
| Revenue Growth (YoY) | 9.88% | 15.45% | 26.78% | 14.92% | 30.89% | 25.76% | Upgrade
|
| Cost of Revenue | 17,528 | 15,795 | 13,226 | 10,385 | 8,993 | 6,752 | Upgrade
|
| Gross Profit | 9,011 | 8,736 | 8,022 | 6,374 | 5,590 | 4,389 | Upgrade
|
| Selling, General & Admin | 7,513 | 6,808 | 6,270 | 5,187 | 4,173 | 3,419 | Upgrade
|
| Research & Development | 92.88 | 80.93 | 74.38 | 44.61 | 4.7 | 0.43 | Upgrade
|
| Other Operating Expenses | 17.71 | 35.32 | 64.57 | 29.94 | 44.27 | 48.68 | Upgrade
|
| Operating Expenses | 7,633 | 6,940 | 6,432 | 5,273 | 4,227 | 3,473 | Upgrade
|
| Operating Income | 1,378 | 1,796 | 1,590 | 1,101 | 1,363 | 916.26 | Upgrade
|
| Interest Expense | -233.16 | -239.26 | -231.97 | -212.04 | -11.5 | -32.05 | Upgrade
|
| Interest & Investment Income | 80.63 | 91.75 | 68.89 | 77.7 | 67.69 | 41.18 | Upgrade
|
| Other Non Operating Income (Expenses) | -34.25 | -49.85 | -48.52 | -29.15 | -29.91 | -23.28 | Upgrade
|
| EBT Excluding Unusual Items | 1,191 | 1,599 | 1,379 | 937.76 | 1,389 | 902.11 | Upgrade
|
| Impairment of Goodwill | -6.21 | -6.21 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -8.87 | 4.38 | -18.71 | 34.57 | 2.75 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 8.08 | 3.43 | 18.73 | 5.63 | -2.53 | -1.64 | Upgrade
|
| Asset Writedown | 12.57 | - | - | - | - | - | Upgrade
|
| Other Unusual Items | 19.72 | 27.05 | 36.36 | 65.94 | 57.33 | 19.03 | Upgrade
|
| Pretax Income | 1,217 | 1,628 | 1,415 | 1,044 | 1,446 | 919.5 | Upgrade
|
| Income Tax Expense | 294.63 | 397.12 | 335.62 | 239.52 | 363.39 | 222.95 | Upgrade
|
| Earnings From Continuing Operations | 922.12 | 1,231 | 1,079 | 804.39 | 1,083 | 696.54 | Upgrade
|
| Minority Interest in Earnings | -71.85 | -64.16 | -43.55 | -13.16 | -20.84 | 6.12 | Upgrade
|
| Net Income | 850.26 | 1,166 | 1,036 | 791.23 | 1,062 | 702.66 | Upgrade
|
| Net Income to Common | 850.26 | 1,166 | 1,036 | 791.23 | 1,062 | 702.66 | Upgrade
|
| Net Income Growth | -33.93% | 12.63% | 30.90% | -25.51% | 51.17% | 32.17% | Upgrade
|
| Shares Outstanding (Basic) | 1,136 | 1,133 | 1,138 | 1,130 | 1,133 | 1,094 | Upgrade
|
| Shares Outstanding (Diluted) | 1,136 | 1,133 | 1,138 | 1,130 | 1,133 | 1,104 | Upgrade
|
| Shares Change (YoY) | -0.25% | -0.50% | 0.69% | -0.24% | 2.65% | 2.13% | Upgrade
|
| EPS (Basic) | 0.75 | 1.03 | 0.91 | 0.70 | 0.94 | 0.64 | Upgrade
|
| EPS (Diluted) | 0.75 | 1.03 | 0.91 | 0.70 | 0.94 | 0.64 | Upgrade
|
| EPS Growth | -33.76% | 13.19% | 30.00% | -25.33% | 47.27% | 29.42% | Upgrade
|
| Free Cash Flow | 1,488 | 1,377 | 2,722 | 260.05 | 1,162 | 1,206 | Upgrade
|
| Free Cash Flow Per Share | 1.31 | 1.22 | 2.39 | 0.23 | 1.03 | 1.09 | Upgrade
|
| Dividend Per Share | 0.620 | 0.310 | 0.500 | 0.347 | 0.463 | 0.289 | Upgrade
|
| Dividend Growth | 24.00% | -38.00% | 43.97% | -24.99% | 60.04% | 29.96% | Upgrade
|
| Gross Margin | 33.95% | 35.61% | 37.76% | 38.03% | 38.33% | 39.39% | Upgrade
|
| Operating Margin | 5.19% | 7.32% | 7.48% | 6.57% | 9.34% | 8.22% | Upgrade
|
| Profit Margin | 3.20% | 4.76% | 4.87% | 4.72% | 7.28% | 6.31% | Upgrade
|
| Free Cash Flow Margin | 5.61% | 5.61% | 12.81% | 1.55% | 7.97% | 10.83% | Upgrade
|
| EBITDA | 1,600 | 2,017 | 1,808 | 1,306 | 1,533 | 1,059 | Upgrade
|
| EBITDA Margin | 6.03% | 8.22% | 8.51% | 7.79% | 10.51% | 9.50% | Upgrade
|
| D&A For EBITDA | 221.51 | 220.03 | 218.06 | 204.62 | 170.77 | 142.65 | Upgrade
|
| EBIT | 1,378 | 1,796 | 1,590 | 1,101 | 1,363 | 916.26 | Upgrade
|
| EBIT Margin | 5.19% | 7.32% | 7.48% | 6.57% | 9.34% | 8.22% | Upgrade
|
| Effective Tax Rate | 24.21% | 24.40% | 23.72% | 22.94% | 25.12% | 24.25% | Upgrade
|
| Revenue as Reported | 26,539 | 24,531 | 21,248 | 16,759 | 14,583 | 11,141 | Upgrade
|
| Advertising Expenses | - | 30.81 | 26.27 | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.